Benralizumab for adults with rare and off-label eosinophilic disorders: a 52-week prospective, single-center study
Benralizumab is safe, well-tolerated, and effective in diverse rare eosinophilic disorders, enabling corticosteroid discontinuation and symptom control. These findings support its broader therapeutic potential and warrant further investigation.
Authors
- Avner Nevo
- Alon Y. Hershko (ORCID: https://orcid.org/0000-0002-7602-483X)
- Aviv Talmon
- Yuval Tal (ORCID: https://orcid.org/0000-0002-3633-2520)
- Limor Rubin (ORCID: https://orcid.org/0000-0001-5435-9420)
- Yaarit Ribak
- Oded Shamriz (ORCID: https://orcid.org/0000-0003-3188-2707)
- Esther Forkosh
- Anna Elia
- Melanie Sion (ORCID: https://orcid.org/0000-0001-7101-8986)
- Iris Aynor
Institutions
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- Concern Foundation (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.3389/fimmu.2025.1702989
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.00